Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529957 | 0.85 | KDM4E (0.59) | KDM4EMGLLPOLBLMNAHPGD | |
| SCHEMBL4871235 | 0.85 | KDM4E (0.56) | KDM4EMGLLPOLBLMNAHPGD | |
| SCHEMBL2533431 | 0.84 | KDM4E (0.55) | KDM4EMGLLPOLBLMNAHPGD | |
| SCHEMBL2527618 | 0.83 | KDM4E (0.53) | KDM4EMGLLPOLBLMNAHPGD | |
| SCHEMBL2533853 | 0.83 | KDM4E (0.53) | KDM4EMGLLPOLBLMNAHPGD | |
| SCHEMBL29956794 | 0.81 | MGLL (0.56) | MGLLPOLBALDH1A1RAB9ANPC1 | |
| SCHEMBL29956428 | 0.81 | — | — | |
| SCHEMBL2529867 | 0.81 | KDM4E (0.56) | KDM4EMGLLPOLBLMNAHPGD | |
| SCHEMBL4878443 | 0.80 | MGLL (0.57) | KDM4EMGLLPOLBLMNAHPGD | |
| SCHEMBL5220709 | 0.80 | KDM4E (0.56) | KDM4EMGLLPOLBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | KDM4E 3671/4885MGLL 3934/4885POLB 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.